‘Off-the-Shelf’ Fix Stops Lethal Stem Cell Transplant Flaw – Medscape
Medscape |
‘Off-the-Shelf’ Fix Stops Lethal Stem Cell Transplant Flaw
Medscape PHILADELPHIA — Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes (CTLs) generated from a bank of normal donor T cells put aggressive EBV-associated lymphoproliferative disorder (LPD) refractory to rituximab into long-lasting remission in more … New T Cell–based Immunotherapy Shows Promise for Lethal Stem Cell …HealthCanal.com Breakthrough T-Cell Therapy Halts EBV-Associated Lymphoproliferative DisordersOncLive |
|
‘Stem cell doc’ faces estafa, illegal practice of medicine
ABS CBN News MANILA – The father of the Ateneo de Manila University student who took stem cell procedures from a “fake” doctor fell short of the justice he was seeking after fiscals filed estafa and illegal practice of medicine, and not murder and syndicated estafa … |
|
‘Stem cell doc’ faces estafa, illegal practice of medicine
ABS CBN News MANILA – The father of the Ateneo de Manila University student who took stem cell procedures from a “fake” doctor fell short of the justice he was seeking after fiscals filed estafa and illegal practice of medicine, and not murder and syndicated estafa … |
Milwaukee Journal Sentinel |
Sale of Madison company could be a big step for stem cell research
Milwaukee Journal Sentinel Su-Chun Zhang, professor of neuroscience in the School of Medicine and Public Health, talks with his staff as they prepare stem cell cultures in Zhang’s research lab at the Waisman Center at the University of Wisconsin-Madison. The university is a stem … Subsequent step for stem cell researchStandard Bulletin |
Milwaukee Journal Sentinel |
Sale of Madison company could be a big step for stem cell research
Milwaukee Journal Sentinel Su-Chun Zhang, professor of neuroscience in the School of Medicine and Public Health, talks with his staff as they prepare stem cell cultures in Zhang’s research lab at the Waisman Center at the University of Wisconsin-Madison. The university is a stem … Subsequent step for stem cell researchStandard Bulletin |
|
Adam Feuerstein Is A Skeptic Of Stem Cell Therapy
Benzinga “I think it’s a very difficult area of drug development, it has not shown much promise,” Feuerstein said. The columnist pointed out that another stem cell related company, Athersys, Inc. (NASDAQ: ATHX), was “blowing up” Friday because its stroke study … |
|
Adam Feuerstein Is A Skeptic Of Stem Cell Therapy
Benzinga “I think it’s a very difficult area of drug development, it has not shown much promise,” Feuerstein said. The columnist pointed out that another stem cell related company, Athersys, Inc. (NASDAQ: ATHX), was “blowing up” Friday because its stroke study … |